ACS Chemical Health & Safety最新文献

{"title":"Optimizing post-transplantation outcomes: the role of multi-omics, artificial intelligence, and animal models in addressing immunosuppression-associated hepatotoxicity","authors":"Yongguang Liu, Runtao Feng, Jianrong Chen, Hongyan Yan, Xiaoyou Liu","doi":"10.1097/js9.0000000000001521","DOIUrl":"https://doi.org/10.1097/js9.0000000000001521","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"95 S4","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer (Experimental Studies)","authors":"J. Meng, Yilan Yang, Jiaojie Lv, Hong Lv, Xu Zhao, Li Zhang, Wei Shi, Zhaozhi Yang, X. Mei, Xing-Xing Chen, Jinli Ma, Zhen Zhang, Zhimin Shao, Xiaoli Yu, Xiaomao Guo","doi":"10.1097/js9.0000000000001546","DOIUrl":"https://doi.org/10.1097/js9.0000000000001546","url":null,"abstract":"\u0000 \u0000 The chemokine receptor CXCR6 is critical for sustained tumor control mediated by CD8+ cytotoxic T cells (CTLs) in tumors. Previous studies have shown that ionizing radiation induces an inflamed immune contexture by upregulating CXCR6. However, the clinical significance of CXCR6 expression in triple-negative breast cancer (TNBC) and its correlation with radiotherapy remains unknown. This study aimed to clarify the prognostic value of CXCR6 and its role in the breast tumor microenvironment (TME).\u0000 \u0000 \u0000 \u0000 The mRNA and protein expression of CXCR6 in human triple-negative breast cancer and their association with survival were analyzed. The role of CXCR6 in the immune context was investigated using a combination of single-cell RNA sequencing, general transcriptome sequencing data and fluorescence-based multiplex immunohistochemistry (mIHC) techniques.\u0000 \u0000 \u0000 \u0000 Elevated CXCR6 expression correlated with better clinical outcomes and superior response to adjuvant radiotherapy and immunotherapy in TNBC. CXCR6 fostered an immunostimulatory microenvironment characterized by upregulated cytotoxic markers. We also found that CXCR6 plays a crucial role in regulating the differentiation of CD8+ T cells and the intercellular communication of immune cell subtypes, shaping the anti-tumor microenvironment.\u0000 \u0000 \u0000 \u0000 This study highlights the emerging role of CXCR6 in shaping the antitumor immune microenvironment, and targeting CXCR6 may be a promising strategy for improving the effectiveness of radiotherapy and immunotherapy in TNBC.\u0000","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"107 4","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141016176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive vision- AI automation of the surgical eye in fluorescence angiography. Correspondence","authors":"R. Cahill","doi":"10.1097/js9.0000000000001496","DOIUrl":"https://doi.org/10.1097/js9.0000000000001496","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"17 S20","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141016620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the understanding of association between breast-conserving surgery with a lower incidence of suicide among females with breast cancer","authors":"ZuJun Wen","doi":"10.1097/js9.0000000000001530","DOIUrl":"https://doi.org/10.1097/js9.0000000000001530","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"150 6","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141015209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor: Effect of pre-transplant viral therapy on post-transplant hepatitis B virus reactivation in patients with hepatitis B-related hepatocellular carcinoma","authors":"Shengke Zhang, Shangke Huang, Guanhu Yang, Hao Chi","doi":"10.1097/js9.0000000000001553","DOIUrl":"https://doi.org/10.1097/js9.0000000000001553","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"119 23","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141017313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A commentary on “concerns regarding “metabolic syndrome and surgical complications: A systematic review and meta-analysis of 13 million individuals”","authors":"Yuquan Chen, Yanwei You, Qi Zhang, Qiang Cao","doi":"10.1097/js9.0000000000001497","DOIUrl":"https://doi.org/10.1097/js9.0000000000001497","url":null,"abstract":"","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"11 5","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141014830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO2-23-12: Innovative Metastatic Breast Cancer Therapy, CBT300, Reverses Drug and Immune Resistance","authors":"Elizabeth Stolarik, Jorryn Zelek, Mariah Thigpen, Anita Davidson, Donald J. Davidson","doi":"10.1158/1538-7445.sabcs23-po2-23-12","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-23-12","url":null,"abstract":"\u0000 For many patients with metastatic breast cancer (MBC), their disease is treatable but incurable. Although the rate of death from MBC has significantly decreased over the last 10 years due to early detection and new treatment options, MBC still accounts for over 40,000 deaths each year in the US that has been consistent for the past 30 years. Recently, it is estimated that 90% of those deaths were due to drug resistant recurrent disease. Nearly 45% of MBC deaths can be attributed to a subpopulation of patients with metastatic triple negative breast cancer (mTNBC). Despite MBC’s initial sensitivity to chemotherapy, it often recurs at greater than 40% in stage I-III patients and greater than 80% in stage IV patients which have a dismal 5-year survival of 12%. African American women have a 40% greater incidence of death from MBC despite a 4% lower risk of diagnosis. Unfortunately, current therapies do little to reduce drug resistance and death for recurrent drug resistant MBC.\u0000 Currently, the only therapies approved by the FDA for recurrent TNBC patients are Keytruda plus chemotherapy and an Antibody Drug Conjugate (ADC) called Sacituzumab Govitecan. Keytruda (anti-PD-L1) is an immune checkpoint inhibitor(ICI) given with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin). The second recently approved therapy, Sacituzumab Govitecan (SG), is composed of an antibody to human trophoblast cell-surface antigen 2 (Trpo-2) coupled to SN-38 (topoisomerase I inhibitor). Although these results are very encouraging, the 80% of TNBC patients that either do not have high positive PD-L1 tumors, or don’t respond to these therapies and become drug resistant suggests that most patients with TNBC will have recurrent disease with little or no hope for survival.\u0000 For contrast, our novel MBC therapy, CBT300, targets cell surface GRP78 that has been found in over 95% of MBC and in 93% of TNBC tumors. We can now show that inhibition of cell surface GRP78 can a) induce apoptosis of drug resistant TNBC cells in vitro and in vivo, b) eliminate drug resistance showing synergistic effects with chemotherapy in vitro and in vivo, c) decrease amount of chemotherapy in combination with CBT300 and d) reduce immune suppression. Recent publications show that GRP78 is found on many types of tumor cell surfaces but not on normal cell surfaces. In fact, tumor cell surface GRP78 (csGRP78) is important for many aspects of MBC development, including cell survival, proliferation, chemoresistance, angiogenesis, metastasis formation, immune suppression, and stem cell formation. Recently, it has been shown that increased cell surface GRP78 expression in TNBC patients was significantly associated with later stage, increased distant metastasis, increased aggressiveness, shorter disease-free survival, and decreased overall survival. In studies to help understand how cell surface GRP78 causes MBC progression and drug resistance, we discovered a novel GRP78 binding transmemb","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"77 5","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141021904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO1-07-08: Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic","authors":"Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnès Bourcier, Geoffroy Canlorbe, C. Uzan","doi":"10.1158/1538-7445.sabcs23-po1-07-08","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po1-07-08","url":null,"abstract":"\u0000 BACKGROUND: Full field optical coherence tomography combined to dynamic cell imaging (D-FFOCT) is a new, simple to use, nondestructive, quick technique than can provide sufficient spatial resolution to mimic histopathological analysis. The objective of this study was to evaluate diagnostic performance of D-FFOCT for one-stop rapid diagnosis breast clinic. METHODS: D-FFOCT was applied to fresh untreated breast and nodes biopsies. Four different readers (senior and junior radiologist, surgeon and pathologist) analyzed the samples without knowing final histological diagnosis or ACR classification. The results were compared to conventional processing and staining (Hematoxylin-eosin). RESULTS: A total of 217 biopsies were performed on 152 patients. There were 144 breast biopsies and 61 lymph nodes with 101 infiltrative cancers (49,27%), 99 benign lesions (48,29%), 3 ductal in situ carcinoma (1,46%) and 2 atypias (0,98%). The diagnostic performances results were as follow: sensitivity: 77% [0.7;0.82], specificity: 64% [0.58;0.71], PPV: 74% [0.68;0.78] and NPV: 75% [0.72;0.78]. A large images atlas was created as well as a diagnosis algorithm from the readers experience. CONCLUSION: D-FFOCT provides interesting results defining malignancy on fresh breast and nodes samples. By training with the diagnosis algorithm and the images atlas or by using machine learning, radiologists could obtain even better outcomes allowing quick detection of breast cancer and lymph node involvement.\u0000 diagnosis algorithm\u0000 Figure 1 Images in DCI and FFOCT\u0000 Two infiltrating cancer diagnosed on pathology (A,B). Focusing on cells (C). Normal galactophoric duct (D). Adenofibroma (E)\u0000 Citation Format: Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnes Bourcier, Geoffroy Canlorbe, Catherine Uzan. Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-08.","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"62 6","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO2-12-11: Ocular Toxicity of Tamoxifen in Patients with Breast Cancer","authors":"Husain Alhouz, Arwa Azmeh, Maher S Saifo","doi":"10.1158/1538-7445.sabcs23-po2-12-11","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-12-11","url":null,"abstract":"\u0000 Background: The latest recommendations in breast cancer treatment protocols with tamoxifen indicate that it should be used from five to 10 years. It depends mainly on the cumulative dose of the drug in the body. Despite its multiplicity, the various studies conducted on this subject did not reach conclusive results. Objectives: This research aims to study retinopathy associated with hormonal treatment of breast cancer using tamoxifen. Methods: A cross-sectional study was conducted at Al-Mouwasat University Hospital on a sample of 130 eyes according to (G-Power) with a statistical power of 95%. The participants were briefed on the research and consented on the ethical considerations. Then, the patients who entered the study were interrogated, clinically examined, and were asked about their medical history, the time of breast cancer diagnosis along with the details about the treatment protocols they underwent or currently undergoing. The refractive errors were measured with an automatic refractive device, then they were examined on the slit lamp to investigate the refractory media, then the corrected and uncorrected visual acuity were taken. Finally, after ensuring that the inclusion criteria were met and excluding those who fulfil one or more of the exclusion criteria, optical coherence tomography was performed using SD-OCT technique to measure and review the retinal thickness map in circles of 1-3-6 mm, respectively, to notice possible changes on it. Results: We found that the use of tamoxifen irrespective to cumulative dose leads to increase in the macula thickness values in the upper and lower sectors within the 3 mm circle, and to significant decrease in the macula thickness values in the upper and lower sectors within the 6 mm circle, in addition to decrease in nasal sector thickness within the circles of 3 and 6 mm. Conclusion: We conclude that the difference between people treated with tamoxifen and those not treated with it is not limited to the occurrence of crystals deposition in the macular area or the presence of a cavity in the central macula (with or without typical cystic macular edema), but rather to existence of macula thickness differences unrelated to the cumulative dose of the drug, whether by increase or decrease in thickness of the upper, lower and nasal segments.\u0000 Citation Format: Husain Alhouz, Arwa Azmeh, Maher Saifo. Ocular Toxicity of Tamoxifen in Patients with Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-11.","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"14 5","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO2-12-05: Scalp Cooling with the Capelli System to Reduce Doxorubicin-induced Alopecia in Patients with Localized Breast Cancer: A Phase 2 Randomized Controlled Trial","authors":"Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, C. Souza, D. Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto","doi":"10.1158/1538-7445.sabcs23-po2-12-05","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs23-po2-12-05","url":null,"abstract":"\u0000 Introduction: Chemotherapy-induced alopecia (CIA) is a distressing side effect of breast cancer (BC) treatment. Scalp cooling (SC) devices have shown promise in reducing the severity of CIA. However, the impact of reducing alopecia occurrence on the quality of life of Brazilian patients remains unclear.\u0000 Objectives: This study aimed to assess the effectiveness of the Capelli System, a new SC device, in reducing CIA.\u0000 Methods: This was a single-center, controlled, randomized phase 2 clinical trial involving women with TNM stage I to III BC undergoing neoadjuvant or adjuvant doxorubicin-based chemotherapy (AC regimen: doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², i.v., q21 days), with or without a taxane (paclitaxel or docetaxel). Participants were randomized in a 1:3 ratio into the scalp cooling (n = 33) or control (n = 12) groups. All participants were advised to cut their hair short and avoid heat-inducing tools or processes throughout chemotherapy, using cold or lukewarm water and wide-toothed combs for hair washing. The primary efficacy endpoint was grade 2 alopecia (>50% hair loss or hair shaving due to alopecia) after 4 cycles of AC. Secondary endpoints included measures of hair loss distress (BRHL) and body image (BRBI) from the EORTC Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ-BR23), as well as symptoms of anxiety and depression from the Hospital Anxiety and Depression Scale (HADS). Fitzpatrick phototype and hair type were assessed. Statistical analyses utilized generalized linear models and Fisher's Exact test (p-value < 0.05).\u0000 Results: Patients were enrolled from October 11, 2019, to January 17, 2022. Out of the 45 patients included, 8 were excluded: 2 due to intolerance, 1 with alopecia associated with COVID-19, and 5 who withdrew consent (2 with grade 2 headache, 3 without justification). The median age was 44.6 (min-max: 23-63) years, with 18 (40%) and 27 (60%) receiving adjuvant and neoadjuvant chemotherapy, respectively. Grade 2 alopecia or hair shaving occurred in 52% of scalp cooling patients and 100% of controls (p = 0.003), demonstrating a significant 48% reduction in alopecia. There were no significant differences in HADS-A, HADS-D, BRHL, or BRBI scores between the two groups. Alopecia occurrence did not show significant associations with skin or hair types. No serious adverse events related to the scalp cooling device were reported.\u0000 Conclusions: SC with the Capelli System significantly reduced CIA by half. Some patients experienced discomfort or headaches and discontinued device use. Further research is needed to understand why reduced alopecia rates do not correlate with improvements in body image or reduced hair loss distress.\u0000 Citation Format: Carlos Paiva, Fabiola Dias, Angelo Matthes, Bianca Paiva, Cristiano Souza, Domício Lacerda, Augusto Antoniazzi, Maria Fernanda Machado, Matheus Godinho, Crislaine de Lima, Cristiane Cárcano, Marina Zorzetto. Scalp Cooling with the Capelli System to Redu","PeriodicalId":12,"journal":{"name":"ACS Chemical Health & Safety","volume":"61 2","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141022245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}